GNRH1 and prostate cancer: Exposure to any form of ADT among prostate cancer patients was followed by an increased risk of adenocarcinoma of the distal colon (HR 1.53 [95% CI 1.26–1.85]), particularly after exposure to GnRH + flare (HR 1.59 [95% CI 1.21–2.08]) (Table 2B).